Dan Kang is an associate in the Corporate Department and a member of the Mergers & Acquisitions Group. His practice focuses on mergers and acquisitions, takeovers, carve-outs and other significant transactions across a variety of industries, including healthcare and life sciences, industrials, energy, consumer products and information technology. He also advises clients on activist defense and corporate governance matters.
Dan’s experience includes advising:
- 3G Capital in its approximately $9 billion acquisition of Skechers U.S.A.
- Amazon in its proposed $1.4 billion acquisition of iRobot
- Carrier Global Corporation in its $3 billion sale of its commercial and residential fire business to an affiliate of Lone Star Funds
- Chevron Corporation in its $7.6 billion acquisition of PDC Energy
- Crown Castle in the combined $8.5 billion sale of its small cells business to EQT Active Core Infrastructure fund and the sale of its fiber solutions business to Zayo Group Holdings
- Dana Incorporated in its $2.7 billion sale of its off-highway business to Allison Transmission Holdings
- Endeavor Energy Resources in its $26 billion merger with Diamondback Energy
- GSK in its $2 billion acquisition of BELLUS Health
- Inhibrx in the $2.2 billion sale of INBRX-101 to Sanofi and the related spin-off of Inhibrx’s non-INBRX-101 business
- Metsera in its $10 billion sale to Pfizer, following a series of competing bids for the company by Pfizer and Novo Nordisk
- QXO in its $17 billion acquisition of TopBuild and successful $11 billion unsolicited bid to acquire Beacon Roofing Supply
- Verve Therapeutics in its $1.3 billion acquisition by Eli Lilly
